• ViroGates posted H1 2026 revenue that more than doubled to DKK 5.1 million, up 173% year on year.
• Operating loss narrowed 33% to DKK 3.94 million; net loss improved 47% to DKK 3.2 million.
• Cash and cash equivalents rose to DKK 17.64 million at period-end.
• Growth was driven largely by deliveries to U.S. partner suPARbio under a minimum binding order to build stock for rollout.
• Guidance reiterated for 2026 revenue of DKK 6.5-8 million; EBIT expected at DKK -10 million to -12 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ViroGates A/S published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.